Flu activity rising in New Hampshire

Influenza activity in New Hampshire is rising, and health experts expect case counts to continue increasing due to holiday gatherings and colder weather driving people indoors. The development is primarily a public-health concern but could modestly raise local healthcare utilization and short-term absenteeism, with limited, localized implications for staffing and consumer activity in affected sectors.

Analysis

Market structure: Rising flu activity is a near-term demand shock for diagnostics, retail pharmacies and hospitals — direct winners include Abbott (ABT), QuidelOrtho (QDEL), CVS (CVS) and Walgreens (WBA) for testing, OTC remedies and vaccine administration; hospitals (HCA) see incremental admissions. Manufacturers of antivirals/vaccines (JNJ, PFE) get modest upside but face capacity and timing limits; discretionary retailers and airlines risk localized weakness during holiday travel. Expect a 4–12 week elevated revenue window concentrated in outpatient testing and pharmacy channels, with limited long-term pricing power for commoditized OTC products.

Risk assessment: Tail risks include emergence of a severe A-strain or significant influenza–COVID co-circulation that triggers school/work closures and government interventions, which would drive sharper but short-lived hits to travel/recreation equities and stress hospital capacity. Time horizons: immediate (days–weeks) for diagnostic kit and shot volumes, short-term (1–3 months) for pharmacy comps, and longer-term (quarters) only if a new strain alters vaccine uptake or reimbursement. Hidden dependencies: insurer reimbursement cadence for point-of-care tests, retail staffing shortages, and regional cold snaps that amplify spread.

Trade implications: Favor tactical long exposure to ABT and QDEL over the next 4–10 weeks via modest equity positions or 30–90 day calls (targeting 5–15% OTM strikes) to capture testing demand; buy CVS/WBA for 4–12 week phasing of shot revenue and harvest premium via covered calls 6–10% OTM. Hedging: buy short-dated puts on airlines (AAL/UAL) sized ~0.5–1% portfolio to protect against travel disruption; consider pair trades long diagnostics (ABT) vs short airlines (AAL) for relative-strength.

Contrarian angles: Consensus underestimates outpatient testing resurgence — many names priced for “no-testing” base case after COVID fatigue, so diagnostics are under-owned relative to potential 20–50% short-term volume spikes. Conversely, big pharma vaccine upside may be overbaked into sector multiples; beware inventory/reimbursement frictions that can cap realized revenue. Action hinge: scale up diagnostics/pharmacy longs if CDC ILI rate increases week-over-week >20% or state test positivity rises above 5% within 7 days.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long in Abbott (ABT) via equity or buy Feb 2026 (30–60 day) calls 5–10% OTM to capture a 4–10 week testing-volume spike; monitor weekly sales cadence and scale +1% if CDC ILI rises >20% week-over-week.
• Initiate a 2% long position in CVS Health (CVS) to capture flu shot and OTC lift for the next 4–12 weeks; sell 30–60 day covered calls 6–8% OTM to monetize any neutral outcome and reduce basis.
• Buy 0.5–1% portfolio protection via 30–45 day puts on American Airlines (AAL) or United (UAL) (5–10% OTM) to hedge holiday travel disruption risk tied to rising flu and staffing shortages.
• Execute a relative trade: long 1.5% QuidelOrtho (QDEL) vs short 1% American Airlines (AAL) to play diagnostics upside against travel downside over the next 4–8 weeks.
• Trigger-based rule: if CDC national/state ILI >3% or test positivity rises >5% with a 2-week increasing trend, increase diagnostics/pharmacy exposure by +1–2% and reduce leisure/travel cyclicals by −1–2% within 7 trading days.